Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 2) [2010] FCA 1212

Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 2) [2010] FCA 1212

Wyeth, the patent holder, was wholly successful; the applicants failed to discharge their burden to obtain a stay or interlocutory orders. The Court granted final relief (injunctions restraining infringement), refused to grant stays or require undertakings from Wyeth beyond those voluntarily given, and made usual orders as to costs in each proceeding. Confidentiality orders were made only for limited evidence relating to Alphapharm's product, as supported by commercial sensitivity and lack of public domain disclosure.

Parties
Applicant / Cross Respondent: Sigma Pharmaceuticals (Australia) Pty Ltd; Applicant / Cross Respondent: Alphapharm Pty Limited; Applicant / Cross Respondent: Generic Health Pty Ltd; First Respondent / First Cross Claimant: Wyeth; Second Respondent / Second Cross Claimant: Wyeth Australia Pty Limited
Jurisdiction
Australia
Judgment Date
08 November 2010
Procedural Posture
Patent Infringement and Revocation Applications (multiple Consolidated Proceedings) / Final Judgment After Hearing and Submissions
Outcome
Applications for revocation dismissed; declarations of threatened infringement made; injunctions granted restraining applicants from infringing certain patent claims; confidentiality orders made for limited evidence; stay orders granted only for specific orders pending appeal; usual orders for costs against each...
Legal Topics
Patent Infringement, Validity of Patent, Staying Injunctions Pending Appeal, Confidentiality Orders, Costs and Apportionment
Intellectual Property Civil Procedure Patent Infringement Validity of Patent Staying Injunctions Pending Appeal Confidentiality Orders Costs and Apportionment

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 6 Authorities cited 21 Party arguments 2
Sign in to unlock

Parties

Sigma Pharmaceuticals (Australia) Pty Ltd

Applicant / Cross Respondent

Alphapharm Pty Limited

Applicant / Cross Respondent

Generic Health Pty Ltd

Applicant / Cross Respondent

Wyeth

First Respondent / First Cross Claimant

Wyeth Australia Pty Limited

Second Respondent / Second Cross Claimant

Procedural Posture

Patent Infringement and Revocation Applications (multiple Consolidated Proceedings) / Final Judgment After Hearing and Submissions

Legal Issues

  1. 1 Whether applicants threatened to infringe claims of Australian Patent No 2003259586
  2. 2 Validity and revocation of the patent
  3. 3 Appropriateness and scope of confidentiality orders

Ratio Decidendi

Wyeth, the patent holder, was wholly successful; the applicants failed to discharge their burden to obtain a stay or interlocutory orders. The Court granted final relief (injunctions restraining infringement), refused to grant stays or require undertakings from Wyeth beyond those voluntarily given, and made usual orders as to costs in each proceeding. Confidentiality orders were made only for limited evidence relating to Alphapharm's product, as supported by commercial sensitivity and lack of public domain disclosure.

Court Disposition

Applications for revocation dismissed; declarations of threatened infringement made; injunctions granted restraining applicants from infringing certain patent claims; confidentiality orders made for limited evidence; stay orders granted only for specific orders pending appeal; usual orders for costs against each...

Orders

  • Applicants restrained from infringing claims 1, 4, 5, 8, 9, 10, 15, 16 and 27 of Australian Patent No 2003259586 by specified acts in Australia.
  • Applicants to destroy relevant infringing products within 14 days and provide affidavit verifying compliance.